1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsNIGMS Technology Development R21 and R01 Programs is sponsored by National Institute of General Medical Sciences (NIGMS). NIGMS supports basic research that increases understanding of biological processes. This program focuses on technology development that supports this mission and is not responsive to disease-specific or organ-specific NIH Institutes or Centers.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NIGMS Technology Development Programs (R21 and R01) | National Institute of General Medical Sciences NIGMS Technology Development Programs (R21 and R01): The advance biomedical research.
Example technologies, which might originate from biomedical, engineering, or physical sciences disciplines, include instruments, devices, processes, algorithms, software, chemicals, biomolecules, or cells that have potential value for generating new basic biomedical research.
The NOFOs support the earliest stages of technology development, establishing feasibility/proof of concept, and prototype validation, and do not support applications that address new biological questions. Investigators are strongly encouraged to contact program staff ( NIGMS_TechDev@nigms. nih.
gov ) prior to and in preparation for submitting an application to these programs.
Proof of Concept and Value Exploratory Research / Technology Feasibility Technology Development R21 Iterative Technology R&D / Validation Studies Technology Development R01 Addressing Biological Questions Applied technology R&D and Dissemination Testing Biological Questions Late-Stage Technology Optimization for Broad Utility and Self-Sustaining Dissemination Biomedical Technology Optimization & Dissemination RM1 Frequently Asked Questions Send your questions about the programs to the NIGMS tech dev contact mailbox .
Technology Commercialization through Small Business Concept to Clinic: Commercializing Innovation Program This page last updated on
According to the current listing, eligibility includes: Researchers and institutions whose projects align with NIGMS's mission of basic biomedical research. Specific eligibility for R21 and R01 mechanisms apply. Confirm the full requirements in the official notice before applying.
The current listing shows R21: Up to $275,000 Direct Costs for 2 years; R01: Not limited, reflects project needs. Verify award ceilings, matching requirements, and allowable costs in the official notice.
NIGMS Technology Development R21 and R01 Programs is funded by National Institute of General Medical Sciences (NIGMS). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The grantmaker formerly known as Open Philanthropy has two open calls that invert normal grant craft: Project Tailwind backs AI safety founders with $200k to $200M on a rolling basis, and Launchpad Funds seeds new global health funds led by a single accountable general manager. Expressions of interest close October 2, 2026.
Read articlePAR-27-056 replaces the long-running IDeA-CTR U54 cooperative agreement with a P30 center core grant and splits the program into Development and Network tracks. Posted August 19, 2026, with a first estimated due date of October 9. Here is what the mechanism swap actually changes for the 23 IDeA states and Puerto Rico.
Read articleThe memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read article